Trial intelligence / Profile preview

Phase 3 darvadstrocel study in pediatric Crohn's disease with complex perianal fistula

NL-OMON60450Phase 3Completed

Sponsor
Takeda
Start
Sep 2021
Modality
Stem Cell Therapies → Cell Therapies
Countries
1
01

Overview

Phase 3 trial of darvadstrocel in Crohn's disease and anal fistula, sponsored by Takeda. Primary endpoint: Combined remission at Week 24. Started Sep 2021; status: completed.

02

Drugs

darvadstrocel
03

Conditions

Crohn's diseaseanal fistula

Beyond the preview

Go deeper on NL-OMON60450.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON60450.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call